Novo Nordisk A/S (NYSE:NVO) Shares Sold by Princeton Capital Management LLC

Princeton Capital Management LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 46.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,668 shares of the company's stock after selling 22,619 shares during the quarter. Novo Nordisk A/S comprises 0.6% of Princeton Capital Management LLC's investment portfolio, making the stock its 26th largest holding. Princeton Capital Management LLC's holdings in Novo Nordisk A/S were worth $1,782,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after purchasing an additional 200 shares in the last quarter. Xponance Inc. boosted its position in shares of Novo Nordisk A/S by 4.9% during the 4th quarter. Xponance Inc. now owns 3,156 shares of the company's stock worth $271,000 after purchasing an additional 146 shares in the last quarter. Congress Wealth Management LLC DE boosted its position in shares of Novo Nordisk A/S by 7.8% during the 4th quarter. Congress Wealth Management LLC DE now owns 18,079 shares of the company's stock worth $1,555,000 after purchasing an additional 1,303 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $530,000. Finally, Graney & King LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $52,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NVO stock traded up $0.94 during trading on Friday, hitting $71.67. The stock had a trading volume of 7,345,265 shares, compared to its average volume of 7,144,964. The company's 50 day moving average price is $70.67 and its two-hundred day moving average price is $73.80. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74. The stock has a market cap of $320.00 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.